Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study. Issue 11 (19th September 2022)

• Record Type: Journal Article
• Authors: Zhang, Xiang; Tu, Yuqing; Shen, Juan; Feng, Yufeng; Ma, Houshi; Bai, Lian; Li, Xiaoli; Lin, Zhihong; Dai, Lijun; Gong, Feiran; Lu, Tianyu; Zhou, Jiazi; Chen, Hanqing; Lv, Quansheng; Zhu, Ziling; Ruan, Changgeng
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 11(2022)
• Page Start: 2636
• Page End: 2644
• Publication Date: 2022-09-19
• Subjects: Leukapheresis -- hyperleukocytic leukemia -- clearance efficiency; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2086246
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Leukapheresis is an effective adjuvant therapy for leukemia patients with hyperleukocytosis, but few studies have reported recent data with modern modalities and comparisons among different leukemia types. We conducted a retrospective study on leukapheresis among 420 patients with AML, ALL and CML in four local centers. WBC counts decreased significantly ( p < 0.001) postleukapheresis in all three cohorts. Clearance efficiency was higher in acute leukemia patients than CML patients ( p < 0.01). Concomitant leukocytoreduction drugs improved WBC reduction only in AML patients ( p < 0.05). Leukocyte, hemoglobin and platelet levels preleukapheresis might affect the clearance efficiency in AML and/or ALL patients. Hematological toxicities were the major concerns, but most of them were mild, and only 11 patients died of all causes within one week postleukapheresis. In conclusion, leukapheresis can safely reduce the leukemic burden, especially for patients with acute leukemias.